Your search
Results 53 resources
-
Cryptococcus species can cause serious life-threatening infection in solid organ transplant recipients by reactivation of prior infection, post-transplant de novo infection, or donor transmission from the transplanted organ. Although previously reported in the literature, the extent of donor-derived cryptococcosis in the United States has not been documented. We analyzed potential donor-derived Cryptococcus transmission events reported to the Organ Procurement and Transplantation Network...
-
Mycobacterium tuberculosis can be transmitted via organ donation and result in severe outcomes. To better understand donor-derived tuberculosis (DDTB), all potential transmissions reported to the Organ Procurement and Transplantation Network (OPTN) Ad Hoc Disease Transmission Advisory Committee between 2008 and 2018 were analyzed. Among 51 total reports, nine (17%) (9 donors/35 recipients) had ≥ 1 recipient with proven/probable disease transmission. Of these, eight were reported due to...
-
Immunocompromised adults with severe parainfluenza received nebulized DAS181 or placebo for up to 10 days. The primary endpoint was not met, but a subgroup of severely immunocompromised patients experienced a faster return to room air by day 28 (P = .012).
-
We present our institution's protocol for evaluating and transplanting thoracic organs from COVID-19 positive donors and report the outcomes to date. Hearts from donors testing positive for COVID-19 on any test were eligible for transplantation at our institution provided the donor exhibited no evidence of hypercoagulability or COVID-19 induced hyperinflammatory state during terminal hospitalization. Lungs were eligible if the donor first tested PCR positive on nasopharyngeal swab (NPS) for...
-
Mollicute infections, caused by Mycoplasma and Ureaplasma species, are serious complications after lung transplantation; however, understanding of the epidemiology and outcomes of these infections remains limited. We conducted a single-center retrospective study of 1156 consecutive lung transplants performed from 2010-2019. We used log-binomial regression to identify risk factors for infection and analyzed clinical management and outcomes. In total, 27 (2.3%) recipients developed mollicute...
-
Background Few options are available for cytomegalovirus (CMV) treatment in transplant recipients resistant, refractory, or intolerant to approved agents. Letermovir (LET) is approved for prophylaxis in hematopoietic cell transplant (HCT) recipients, but little is known about efficacy in CMV infection. We conducted an observational study to determine the patterns of use and outcome of LET treatment of CMV infection in transplant recipients. Methods Patients who received LET for treatment of...
-
Abstract. These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America (IDSA) in 2009, prior to t
-
Hepatitis B virus (HBV) can be transmitted from organ donor to recipient, but details of transmission events are not widely published. The Disease Transmission Advisory Committee (DTAC) evaluated 105 cases of potential donor derived transmission events of HBV between 2009-2017. Proven, probable or possible transmission of HBV occurred in 25 (23.8%) cases. Recipients of liver grafts were most commonly infected (20 of 21 exposed recipients) compared to 9 of 21 exposed non-hepatic recipients....
-
HIV-positive donor to HIV-positive recipient (HIV D+/R+) transplantation is permitted in the United States under the HIV Organ Policy Equity Act. To explore safety and the risk attributable to an HIV+ donor, we performed a prospective multicenter pilot study comparing HIV D+/R+ vs HIV-negative donor to HIV+ recipient (HIV D−/R+) kidney transplantation (KT). From 3/2016 to 7/2019 at 14 centers, there were 75 HIV+ KTs: 25 D+ and 50 D− (22 recipients from D− with false positive HIV tests)....
-
Organ transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV (HIV D+/R+) presents risks of donor-derived infections. Understanding clinical, immunologic, and virologic characteristics of HIV-positive donors is critical for safety.We performed a prospective study of donors with HIV-positive and HIV false-positive (FP) test results within the HIV Organ Policy Equity (HOPE) Act in Action studies of HIV D+/R+ transplantation (ClinicalTrials.gov NCT02602262,...
Filter by our tag
GUIDELINES
- AST Guidelines 2019 (1)
- IDSA Guidelines (1)
- ISHLT Guidelines (1)
TEXTBOOKS
CORE CURRICULUM
- INTRO SOLID ORGAN TRANSPLANT (1)
-
ORGANISMS
(1)
- Protozoa (1)
- SYNDROMES (2)
ORGANISMS
-
BACTERIA
(10)
- C. difficile (1)
- MDR GNR (4)
- MRSA (2)
- Mycoplasma and Ureaplasma (1)
- Non-tuberculous Mycobacteria (3)
- Tuberculosis (1)
-
FUNGI
(4)
- Candida (1)
- Cryptococcus (1)
- Mucormycosis (1)
- Pneumocystis (1)
-
PARASITES AND PROTOZOA
(3)
- Chagas (1)
- Protozoa (1)
- Strongyloides (1)
-
VIRUSES
(16)
-
CMV
(2)
- Clinical (1)
- Epidemiology and Risk Factors (1)
- Maribavir (1)
-
COVID-19
(2)
- Positive Donors (1)
- Positive Recipients (1)
- Hepatitis B (1)
- Hepatitis C (3)
- HIV (5)
- HPV (1)
- Influenza (1)
- Respiratory Viruses (1)
- WNV (1)
-
CMV
(2)
PREVENTION
- Safe Living (1)
SYNDROMES AND CONDITIONS
- CNS (1)
- Cytopenias (1)
- Pneumonia (1)
SOLID ORGANS AND MCSS
- Donor (8)
- Heart (2)
- Immunosuppression (1)
- Kidney (1)
- Liver (1)
- Lung (2)
- LVAD (1)
- PEDIATRIC (1)
- Vascular Composite Allograft (1)
HEME-ONC AND CELLULAR THERAPIES
- Neutropenia (1)
ARTICLE OF THE MONTH
- 2021 (1)
ATC 2024 Top Papers in TID
- BACTERIA (1)